XML 36 R23.htm IDEA: XBRL DOCUMENT v3.24.2
STOCKHOLDERS’ EQUITY (DEFICIT)
12 Months Ended
Dec. 31, 2023
STOCKHOLDERS' DEFICIT:  
STOCKHOLDERS’ EQUITY (DEFICIT)

NOTE 13 – STOCKHOLDERS’ EQUITY (DEFICIT)

 

Preferred Stock

 

In accordance with the Company’s bylaws, the Company has authorized a total of 2,000,000 shares of preferred stock, par value $0.01 per share, for all classes. As of December 31, 2023 and 2022 respectively, there were 88,335 and 88,335 total preferred shares issued and outstanding for all classes.

 

Common Stock

  

In accordance with the Company’s bylaws, the Company has authorized a total of 20,000,000,000 shares of common stock, par value $0.0001 per share. As of December 31, 2023 and 2022, there were 8,100,117,720 and 6,427,395,360 common shares issued, respectively. As of December 31, 2023 and 2022, there were 8,100,117,720 and 6,427,395,360 common shares outstanding, respectively.

 

2022 Transactions

 

On May 27, 2022 we entered an Equity Financing Agreement (the “EFA”) and Registration Rights Agreement (the “RRA”) with GHS, pursuant to which GHS agreed to purchase up to $70,000,000 in shares of our Common Stock, from time to time over the course of 24 months after effectiveness of a registration statement on Form S-1 (the “Registration Statement”) of the underlying shares of Common Stock.

 

The RRA provides that we shall (i) use our best efforts to file with the SEC a Registration Statement within 45 days of the date of the GHS Registration Rights Agreement; and (ii) have the Registration Statement declared effective by the SEC within 30 days after the date the GHS Registration Statement is filed with the SEC, but in no event more than 90 days after the GHS Registration Statement is filed.

 

2023 Transactions

 

On April 28, 2023 the Company entered into an Equity Financing Agreement with GHS, to which GHS agreed to Purchase $30,000,000 in shares of our Common Stock over the course of 12 months at 92% of the current market price.

 

On June 13, 2023 the Company entered into an Amendment to the 2023 Equity Financing Agreement with GHS, to which GHS agreed to Purchase $30,000,000 in shares of our Common Stock over the course of 12 months at 92% of the current market price.

 

On July 10,2023 the Company entered into a Second Amendment to the 2023 Equity Financing Agreement with GHS, to which GHS agreed to purchase up to $30,000,000 in shares of our Common Stock over the course of 12 months at 92% of the current market price.

 

On September 5, 2023, we entered into a Stock Purchase Agreement with an investor for the purchase of 100,000,000 shares of Common Stock for a total consideration of $100,000.

 

The RRA provides that we shall (i) use our best efforts to file with the SEC a Registration Statement within 45 days of the date of the GHS Registration Rights Agreement; and (ii) have the Registration Statement declared effective by the SEC within 30 days after the date the GHS Registration Statement is filed with the SEC, but in no event more than 90 days after the GHS Registration Statement is filed.

 

The below table of puts from 1/12/2023 through 4/11/2023 were made by the Company under the 2022 EFA during 2023. The put from 4/28/2023 was made under the EFA dated 4/28/2023. The puts from 6/26/2023 and 7/3/2023 were made by the Company under the Amended EFA dated June 13, 2023. The 7/10/2023 put was made by the Company under the Second Amended EFA dated July 10, 2023.

               
Date of Put  Number of Common Shares Issued   Total Proceeds, Net of Discounts   Effective Price per Share  Net Proceeds 
1/12/2023   64,130,435   $400,000   $0.006237  $370,975 
1/17/2023*   11,441,647    100,000   $0.008740   100,000 
1/24/2023   77,733,861    400,000   $0.005146   370,975 
2/3/2023   61,173,706    300,000   $0.004904   277,975 
2/17/2023   75,447,571    300,000   $0.003976   277,975 
3/1/2023   83,113,044    324,000   $0.003898   300,295 
3/16/2023   93,165,852    254,232   $0.002729   235,410 
3/30/2023   65,465,384    166,903   $0.002549   154,195 
4/11/2023   67,462,162    203,554   $0.003017   188,279 
4/28/2023   91,796,875    235,000   $0.002560   208,550 
6/26/2023   44,583,334    214,000   $0.004800   141,020 
7/3/2023   51,442,308    274,058   $0.004200   257,020 
7/10/2023   28,593,750    91,500   $0.003200   85,094 
9/5/2023*   100,000,000    100,000   $0.001000   100,000 
11/7/2023*   55,555,555    50,000   $0.000900   50,000 
11/8/2023*   33,333,333    30,000   $0.000900   30,000 
11/14/2023   18,997,442    25,180   $0.001325   22,392 
11/22/2023   29,685,620    34,717   $0.001169   31,262 
11/29/2023*   55,555,555    50,000   $0.000900   50,000 
11/30/2023*   27,777,777    25,000   $0.000900   25,000 
12/1/2023*   33,333,333    30,000   $0.000900   30,000 
12/1/2023   51,275,586    47,973   $0.000936   43,590 
12/11/2023   87,136,216    108,019   $0.001240   99,433 
12/27/2023   67,522,014    57,909   $0.000858   52,830 
    1,375,722,360   $3,822,044      $3,502,272 

 

In January 2023, the Company entered into a settlement of a dispute between certain stockholders in which the Company decided, during the period ended June 30, 2023, to issue shares to settle the dispute. In January 2023, the Company issued 297,000,000 shares of common stock to the individuals. The fair value of $1,989,900, or $0.0067 per share, was included in professional fees in the consolidated statements of operations for the year ended December 31, 2023. As part of this transaction $280,536 of accrued liabilities have been reversed.

 

Stock Options

 

As of December 31, 2023 and 2022, the Company had no outstanding stock options.